NO20072325L - Combination therapy including telmisartan and hydrochlorothiazide - Google Patents

Combination therapy including telmisartan and hydrochlorothiazide

Info

Publication number
NO20072325L
NO20072325L NO20072325A NO20072325A NO20072325L NO 20072325 L NO20072325 L NO 20072325L NO 20072325 A NO20072325 A NO 20072325A NO 20072325 A NO20072325 A NO 20072325A NO 20072325 L NO20072325 L NO 20072325L
Authority
NO
Norway
Prior art keywords
hydrochlorothiazide
telmisartan
combination therapy
therapy including
approx
Prior art date
Application number
NO20072325A
Other languages
Norwegian (no)
Inventor
Axel Riedel
Helmut E Schumacher
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072325(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20072325L publication Critical patent/NO20072325L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et farmasøytisk preparat omfattende ca. 80 mg telmisartan og ca. 25 mg hydroklortiazid eller ca. 160 mg telmisartan og ca. 50 mg hydroklortiazid for behandling av hypertensjon hos pasienter med en utilstrekkelig blodtrykkreduksjon etter behandling enten med en angiotensin II-reseptorantagonist eller et farmasøytisk preparat av en angiotensin II-reseptorantagonist og en lav dose av hydroklortiazid.A pharmaceutical composition comprising ca. 80 mg telmisartan and approx. 25 mg hydrochlorothiazide or approx. 160 mg telmisartan and approx. 50 mg hydrochlorothiazide for the treatment of hypertension in patients with inadequate blood pressure reduction after treatment with either an angiotensin II receptor antagonist or a pharmaceutical preparation of an angiotensin II receptor antagonist and a low dose of hydrochlorothiazide.

NO20072325A 2004-12-17 2007-05-04 Combination therapy including telmisartan and hydrochlorothiazide NO20072325L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (en) 2004-12-17 2005-12-09 Combination therapy comprising telmisartan and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
NO20072325L true NO20072325L (en) 2007-07-06

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072325A NO20072325L (en) 2004-12-17 2007-05-04 Combination therapy including telmisartan and hydrochlorothiazide

Country Status (15)

Country Link
EP (1) EP1827424A1 (en)
JP (1) JP2008524136A (en)
KR (1) KR20070097511A (en)
CN (1) CN101080225A (en)
AR (1) AR052052A1 (en)
AU (1) AU2005315855A1 (en)
BR (1) BRPI0519656A2 (en)
CA (1) CA2589493A1 (en)
EA (1) EA200701159A1 (en)
IL (1) IL183944A0 (en)
NO (1) NO20072325L (en)
PE (1) PE20060768A1 (en)
TW (1) TW200637546A (en)
UY (1) UY29274A1 (en)
WO (1) WO2006063737A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CA2702904A1 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2009115301A1 (en) 2008-03-19 2009-09-24 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
NZ590948A (en) 2008-07-31 2012-06-29 Takeda Pharmaceutical Solid pharmaceutical composition comprising a diuretic, ph control agent and an oxadiazole
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002423A2 (en) * 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk Multilayer tablet containing telmisartan and hydrochlorothiazide
EP3025711B1 (en) * 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
CN106562973A (en) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 Anti-hypertension medicine compound preparation
CN107501192A (en) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 The eutectic of Telmisartan and Hydrochioro
CN108653227A (en) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 A kind of Telmisartan hydrochlorothiazide tablets and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (en) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated, divisible tablet
CZ303145B6 (en) * 2002-01-16 2012-05-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing bilayer pharmaceutical tablet containing telmisartan and hydrochlorothiazide

Also Published As

Publication number Publication date
PE20060768A1 (en) 2006-09-29
WO2006063737A1 (en) 2006-06-22
IL183944A0 (en) 2007-10-31
EP1827424A1 (en) 2007-09-05
CN101080225A (en) 2007-11-28
TW200637546A (en) 2006-11-01
BRPI0519656A2 (en) 2009-03-03
AU2005315855A1 (en) 2006-06-22
CA2589493A1 (en) 2006-06-22
EA200701159A1 (en) 2007-12-28
AR052052A1 (en) 2007-02-28
KR20070097511A (en) 2007-10-04
JP2008524136A (en) 2008-07-10
UY29274A1 (en) 2006-07-31

Similar Documents

Publication Publication Date Title
NO20072325L (en) Combination therapy including telmisartan and hydrochlorothiazide
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
CL2008003595A1 (en) Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system.
JP6151123B2 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
NO20072931L (en) Improved dosing regimen of temozolomide for the treatment of cancer based on the patient's MGMT level
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
RU2010135831A (en) METHODS, MEDICINAL FORMS AND KITS FOR INTRODUCING ZIPRASIDONE WITHOUT FOOD
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
AR034517A1 (en) PHARMACEUTICAL FORMULATION
WO2010045417A3 (en) Combination therapies for the treatment of obesity
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
WO2007098387A3 (en) Antihypertensive therapy
MX2023000303A (en) Co-agonists at glp-1 and gip receptors suitable for oral delivery.
JP7109092B2 (en) Pharmaceutical patch for the treatment of neuropathic pain containing lidocaine and diclofenac
WO2004096118A3 (en) Composition for improving cognition and memory
CL2007003484A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING VALSARTAN AND A TENSOACTIVE, A LIPOFILIC COMPONENT AND A HYDROPHILIC COMPONENT; PREPARATION PROCEDURE; AND USE IN THE TREATMENT OF CARDIAC INSUFFICIENCY, ANGINA, MIOCARDIO INFARTO, ARTERIOESCLEROS
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
SE9902597D0 (en) New use
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP7109093B2 (en) Dosing Regimens for Pharmaceutical Patches Containing Lidocaine and Diclofenac
NO20061515L (en) Use of oxcarbazepine for the treatment of diabetic neurpathic pain and improvement of sleep
PT1408977E (en) COMBINATION THERAPY FOR CARDIAC FAILURE TREATMENT
ECSP11010999A (en) FIXED DOSAGE COMBINATION IN THE FORM OF A TWO-LAYERED TABLET OR A SINGLE LAYER OF ALISQUIRENE AND AMLODIPINE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application